"US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024" was originally created and ...

JenaValve announced today that it received the green light to begin a new randomized controlled trial for its Trilogy device.

A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...

The 2024 edition of Transcatheter Cardiovascular Therapeutics (TCT) once again highlighted significant innovations in ...

This is due to the increasing prevalence of CVD and metabolic disorders. The global structural heart devices market, valued ...

The ACCESS-TAVI trial demonstrated that a combined suture/plug-based vascular closure device strategy significantly reduces ...

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. Here’s what the results mean for the ...

LONDON — Two years after the large multinational PROTECTED TAVR trial failed to associate a cerebral embolic protection (CEP) device with significant protection from stroke in patients undergoing ...

TTVR also led to "near elimination" of the TR, as 99.1% of people had moderate or less TR (and 95.3% mild or less) at the ...

Zoom in or out of the page as needed for optimal reading comfort. You can also use a pinch gesture to zoom on touch devices.

For patients with symptomatic and severe tricuspid regurgitation (TR), tricuspid transcatheter edge-to-edge repair (T-TEER) ...

Routine use of an orbital atherectomy device to remove calcium from severely blocked coronary arteries before patients ...